Electronic Biological Product Deviation Reports May Trigger ‘Direct’ Recall, CBER Officials Say

Drug Industry Daily
TAMPA, Fla. — Now that CBER’s all-electronic Direct Recall Classification (DRC) program has been extended to non-blood products, problems with biologic drugs flagged in electronic biological product deviation reports (eBPDRs) may trigger recalls of those products under the program.

To View This Article:


Subscribe To Drug Industry Daily